demonstrated that intentional weight loss significantly improved the response of obese PsO patients to low-dose cyclosporine ( Collectively, these data highlight the importance of integrating metabolic health into early therapeutic strategies for PsA, particularly in individuals at high risk of disease progression or in those presenting with subclinical musculoskeletal involvement
doi: 10.3390/ijerph18084381
[1] [2] These medicines include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro), which is a dual GIP/GLP-1 receptor agonist
#TCAPeel and #MicrobiomeSkincare signal growing consumer interest in understanding the mechanisms behind skin behavior, from chemical exfoliation and skin renewal to the role of the microbiome in barrier health
This differs from intramuscular injection and requires specific approach